Escherichia coli–expressed near full length HIV-1 envelope glycoprotein is a highly sensitive and specific diagnostic antigen

BMC Infectious Diseases

Navin Khanna²  Kim Pettersson¹  Tero Soukka¹  Sathyamangalam Swaminathan²  Sushil Kumar²  Teppo Salminen¹  Satish Kumar Nemani²  Sheikh M Talha² 

[1] Department of Biotechnology, University of Turku, 20520, Turku, Finland;Recombinant Gene Products Group, International Centre for Genetic Engineering & Biotechnology, Aruna Asaf Ali Marg, New Delhi, 110067, India

关键词: HIV diagnostics;    Time resolved fluorometry;    Time-resolved fluorescence;    Eu³⁺-chelate;    Expression in E. coli;    Recombinant HIV-1 envelope glycoprotein;   

Others  :  1158778
DOI  :  10.1186/1471-2334-12-325

 received in 2012-05-11, accepted in 2012-11-23,  发布年份 2012

【 摘 要 】

Background

The Human Immunodeficiency Virus type 1 (HIV-1) envelope glycoprotein gp160, useful in detecting anti-HIV-1 antibodies, is difficult to express in heterologous hosts. The major hurdles are its signal sequence, strong hydrophobic regions and heavy glycosylation. While it has not been possible to express full length recombinant (r)-gp160 in E. coli, it can be expressed in insect and mammalian cells, but at relatively higher cost. In this work, we report E. coli-based over-expression of r-gp160 variant and evaluate its performance in diagnostic immunoassays for the detection of anti-HIV-1 antibodies.

Methods

A deletion variant of r-gp160 lacking hydrophobic regions of the parent full length molecule was expressed in E. coli and purified to near homogeneity using single-step Ni(II)-affinity chromatography. Biotinylated and europium(III) chelate-labeled versions of this antigen were used to set up one- and two-step time-resolved fluorometric double antigen sandwich assays. The performance of these assays was evaluated against a collection of well-characterized human sera (n=131), that included an in-house panel and four commercially procured panels.

Results

In-frame deletion of three hydrophobic regions, spanning amino acid residues 1–43, 519–538 and 676–706, of full length HIV-1 gp160 resulted in its expression in E. coli. Both the one- and two-step assays manifested high sensitivity unambiguously identifying 75/77 and 77/77 HIV-1 positive sera, respectively. Both assays also identified all 52 HIV-seronegative sera correctly. Between the two assays, the mean signal-to-cutoff value of the two-step assay was an order of magnitude greater than that of the one-step assay. Both assays were highly specific manifesting no cross-reactivity towards antibodies specific to other viruses like hepatitis B, C, and human T cell leukemia viruses.

Conclusions

This study has demonstrated the expression of r-gp160 variant in E. coli, by deletion of hydrophobic regions, and its purification in reasonable yields. This underscores the potential for cost saving in antigen production. Evaluation of this antigen in a double antigen sandwich two-step assay showed it to be a highly sensitive and specific HIV-1 diagnostic reagent. The amenability of this assay to the one-step format suggests its potential utility in developing a rapid point-of-care HIV-1 diagnostic test.

【 授权许可】

   
2012 Talha et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Kuritzkes DR, Walker BD: HIV-1: pathogenesis, clinical manifestations, and treatment. In Fields virology. 5th edition. Edited by Knipe DM, Howley PM. Philadelphia: Lippincott Williams & Wilkins; 2007:2187-2214.
• [2]UNAIDS world AIDS day report 2011. (accessed on November 23, 2012) [ http://www.unaids.org/en/media/unaids/contentassets/documents/unaidspublication/2011/JC2216_WorldAIDSday_report_2011_en.pdf webcite].
• [3]Chu C, Selwyn PA: Diagnosis and initial management of acute HIV infection. Am Fam Physician 2010, 81(10):1239-1244.
• [4]Klimas N, Koneru AO, Fletcher MA: Overview of HIV. Psychosom Med 2008, 70:523-530.
• [5]Stürmer M, Doerr HW, Gürtler L: Human immunodeficiency virus: 25 years of diagnostic and therapeutic strategies and their impact on hepatitis B and C virus. Med Microbiol Immunol 2009, 198:147-155.
• [6]Buttò S, Suligoi B, Fanales-Belasio E, Raimondo M: Laboratory diagnostics for HIV infection. Ann Ist Super Sanita 2010, 46(1):24-33.
• [7]Daskalakis D: HIV diagnostic testing: evolving technology and testing strategies. Top Antivir Med 2011, 19(1):18-22.
• [8]Yang K, Li S, He F, Zhang J, Wei M, Pan H, Yang C, Xiong J, Zhang J, Xia N: Expression and purification of soluble HIV-1 envelope glycoprotein gp160 mutant from Saccharomyces cerevisiae. J Biosci Bioeng 2009, 108(1):5-10.
• [9]Sohn MJ, Lee ME, Park HS, Nham SU, Lee YI: Overexpression and purification of human immunodeficiency virus type 1 env derived epitopes in Escherichia coli. J Biotechnol 1996, 45(3):211-216.
• [10]Horal P, Svennerholm B, Jeansson S, Rymo L, Hall WW, Vahlne A: Continuous epitopes of the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein and reactivity of human sera to synthetic peptides representing various HIV-1 isolates. J Virol 1991, 65(5):2718-2723.
• [11]Norrby E, Putkonen P, Böttiger B, Utter G, Biberfeld G: Comparison of linear antigenic sites in the envelope proteins of human immunodeficiency virus (HIV) type 2 and type 1. AIDS Res Hum Retrovir 1991, 7(3):279-285.
• [12]Chen J, Wang L, Chen JJ, Sahu GK, Tyring S, Ramsey K, Indrikovs AJ, Petersen JR, Paar D, Cloyd MW: Detection of antibodies to human immunodeficiency virus (HIV) that recognize conformational epitopes of glycoproteins 160 and 41 often allows for early diagnosis of HIV infection. J Infect Dis 2002, 186(3):321-331.
• [13]Saville RD, Constantine NT, Cleghorn FR, Jack N, Bartholomew C, Edwards J, Gomez P, Blattner WA: Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody. J Clin Microbiol 2001, 39(7):2518-2524.
• [14]Lasky LA, Groopman JE, Fennie CW, Benz PM, Capon DJ, Dowbenko DJ, Nakamura GR, Nunes WM, Renz ME, Berman PW: Neutralization of the AIDS retrovirus by antibodies to a recombinant envelope glycoprotein. Science 1986, 233(4760):209-212.
• [15]Berman PW, Riddle L, Nakamura G, Haffar OK, Nunes WM, Skehel P, Byrn R, Groopman J, Matthews T, Gregory T: Expression and immunogenicity of the extracellular domain of the human immunodeficiency virus type 1 envelope glycoprotein, gp160. J Virol 1989, 63(8):3489-3498.
• [16]Nkosi SP, Huismans H, Papathanasopoulos MA: Purification and partial characterization of R5, R5X4, and X4 HIV-1 subtype C envelope glycoproteins expressed in insect cells. J Med Virol 2005, 76(4):459-463.
• [17]Fenouillet E, Miquelis R, Drillien R: Biological properties of recombinant HIV envelope synthesized in CHO glycosylation-mutant cell lines. Virology 1996, 218(1):224-231.
• [18]Jeffs SA, Goriup S, Kebble B, Crane D, Bolgiano B, Sattentau Q, Jones S, Holmes H: Expression and characterisation of recombinant oligomeric envelope glycoproteins derived from primary isolates of HIV-1. Vaccine 2004, 22(8):1032-1046.
• [19]McDonald R, Burnett V: Novel single-round PCR and cloning of full-length envelope genes of HIV-1 may yield new insight into biomolecular antibacterial drug development. J Virol Methods 2005, 126(1–2):111-118.
• [20]Talha SM, Salminen T, Swaminathan S, Soukka T, Pettersson K, Khanna N: A highly sensitive and specific time resolved fluorometric bridge assay for antibodies to HIV-1 and −2. J Virol Methods 2011, 173(1):24-30.
• [21]Batra G, Talha SM, Nemani SK, Dhar N, Swaminathan S, Khanna N: Purification and characterization of in vivo biotinylated dengue virus envelope domain III based tetravalent antigen. Prot Expr Purif 2010, 74(1):99-105.
• [22]Lode PV, Rosenberg J, Pettersson K, Takalo H: A europium chelate for quantitative point-of-care immunoassays using direct surface measurement. Anal Chem 2003, 75:3193-3201.
• [23]Pettersson K, Lode PV, Eriksson S, Lövgren J, Takalo H: Multi-assay point of care platform: highly sensitive time-resolved fluorometric detection in combination with a universal “All-in-one” assay format. Point of care 2003, 2:225-232.
• [24]Mukkala V-M, Hänninen E, Hemmilä I: Synthesis of two biotin isothiocyanate derivatives. In Proceedings of 8th European symposium on organic chemistry. Barcelona, Spain: Book of abstracts. Universitat Autónoma de Barcelona, Sitges; 1993:86.
• [25]Pancera M, Majeed S, Ban YEA, Chen L, Huang CC, Kong L, Kwon YD, Stuckey J, Zhou T, Robinson JE, Schief WR, Sodroski J, Wyatt R, Kwong PD: Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 2010, 107(3):1166-1171.
• [26]Finzi A, Pacheco B, Zeng X, Kwon YD, Kwong PD, Sodroski J: Conformational characterization of aberrant disulfide-linked HIV-1 gp120 dimers secreted from overexpressing cells. J Virol Methods 2010, 168(1–2):155-161.
• [27]Lin CH, Lin CH, Chang CC, Wei TS, Cheng SF, Chen SS, Chang DK: An efficient production and characterization of HIV-1 gp41 ectodomain with fusion peptide in Escherichia coli system. J Biotechnol 2011, 153(1–2):48-55.
• [28]Vogel EP, Curtis-Fisk J, Young KM, Weliky DP: Solid-state nuclear magnetic resonance (NMR) spectroscopy of human immunodeficiency virus gp41 protein that includes the fusion peptide: NMR detection of recombinant Fgp41 in inclusion bodies in whole bacterial cells and structural characterization of purified and membrane-associated Fgp41. Biochemistry 2011, 50(46):10013-10026.
• [29]Batra G, Nemani SK, Tyagi P, Swaminathan S, Khanna N: Evaluation of envelope domain III-based single Chimeric tetravalent antigen and monovalent antigen mixtures for the detection of anti-dengue antibodies in human sera. BMC Infect Dis 2011, 11:64. BioMed Central Full Text
• [30]Siitari H, Turunen P, Schrimsher J, Nunn M: New sensitive and specific assay for human immunodeficiency virus antibodies using labeled recombinant fusion protein and time-resolved fluoroimmunoassay. J Clin Microbiol 1990, 28(9):2022-2029.
• [31]Butch AW: Dilution protocols for detection of hook effects/prozone phenomenon. Clin Chem 2000, 46(10):1719-1721.